Share-based Payment Arrangement, Expense in USD of Rani Therapeutics Holdings, Inc. from Q2 2020 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Rani Therapeutics Holdings, Inc. quarterly and annual Share-based Payment Arrangement, Expense history and change rate from Q2 2020 to Q1 2025.
  • Rani Therapeutics Holdings, Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Mar 2025 was $3,925,000, a 1.42% increase year-over-year.
  • Rani Therapeutics Holdings, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $16,031,000, a 15.7% decline from 2023.
  • Rani Therapeutics Holdings, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $19,008,000, a 20.4% increase from 2022.
  • Rani Therapeutics Holdings, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $15,782,000, a 30.2% decline from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Rani Therapeutics Holdings, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $3,925,000 +$55,000 +1.4% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q1 2024 $3,870,000 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q4 2022 $15,782,000 $4,499,000 +$1,334,000 +42% 01 Oct 2022 31 Dec 2022 10-K 20 Mar 2024 2023 FY
Q3 2022 $14,448,000 $4,402,000 -$14,294,000 -76% 01 Jul 2022 30 Sep 2022 10-Q 10 Nov 2022 2022 Q3
Q2 2022 $28,742,000 $3,976,000 +$3,694,000 +1,310% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2022 2022 Q2
Q1 2022 $25,048,000 $2,905,000 +$2,453,000 +543% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2022 2022 Q1
Q4 2021 $22,595,000 $3,165,000 01 Oct 2021 31 Dec 2021 10-K 22 Mar 2023 2022 FY
Q3 2021 $18,696,000 +$18,696,000 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $282,000 +$282,000 01 Apr 2021 30 Jun 2021 10-Q 10 Aug 2022 2022 Q2
Q1 2021 $452,000 01 Jan 2021 31 Mar 2021 10-Q 11 May 2022 2022 Q1
Q3 2020 $0 01 Jul 2020 30 Sep 2020 10-Q 16 Nov 2021 2021 Q3
Q2 2020 $0 01 Apr 2020 30 Jun 2020 10-Q 13 Sep 2021 2021 Q2

Rani Therapeutics Holdings, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $16,031,000 -$2,977,000 -16% 01 Jan 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
2023 $19,008,000 +$3,226,000 +20% 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
2022 $15,782,000 -$6,813,000 -30% 01 Jan 2022 31 Dec 2022 10-K 20 Mar 2024 2023 FY
2021 $22,595,000 +$22,595,000 01 Jan 2021 31 Dec 2021 10-K 22 Mar 2023 2022 FY
2020 $0 01 Jan 2020 31 Dec 2020 10-K 31 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.